Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Deals

Sino Biopharmaceutical and Sinopharm Group Collaborate to Expand Retail Pharmacy Network

Fineline Cube Dec 18, 2024

In a significant move for China’s pharmaceutical industry, Sino Biopharmaceutical Ltd (HKG: 1177) and Sinopharm...

Company Drug

Everest Medicines’ Velsipity (Etrasimod) Receives First Prescription in Foshan under GBA Policy

Fineline Cube Dec 18, 2024

Everest Medicines (HKG: 1952), a leading biopharmaceutical company based in China, has announced that its...

Company Drug

ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Amulirafusp Alfa in NMOSD

Fineline Cube Dec 18, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced the commencement of...

Company

Henlius Biotech Joins Biosimilars Forum to Expand Global Biosimilars Access

Fineline Cube Dec 18, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading Chinese biopharmaceutical company, has announced its membership...

Company Medical Device

MicroPort CardioFlow Medtech’s VitaFlow Liberty Flex Receives NMPA Approval

Fineline Cube Dec 18, 2024

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a prominent player in the medical device industry...

Company Medical Device

Lepu Scientech’s ScienCcrown TAVR System Earns NMPA Medical Device License

Fineline Cube Dec 18, 2024

Lepu Scientech Medical Technology (Shanghai) Co., Ltd (HKG: 2291), a leading China-based medical technology company,...

Company Drug

Eli Lilly’s Kisunla Receives NMPA Approval for Early Alzheimer’s Disease Treatment

Fineline Cube Dec 18, 2024

Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced...

Company Drug

BioNova Pharmaceuticals’ BN104 Receives Breakthrough Therapy Designation in China

Fineline Cube Dec 18, 2024

The China’s Center for Drug Evaluation (CDE) website has indicated that BioNova Pharmaceuticals (Shanghai) Ltd.’s...

Company Drug

Evopoint Biosciences Submits Pre-NDA for Funobactam, Imipenem, and Cilastatin to NMPA

Fineline Cube Dec 18, 2024

Suzhou-based Evopoint Biosciences Co., Ltd. has announced the submission of a Pre-NDA (New Drug Application)...

Company Deals

Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform

Fineline Cube Dec 18, 2024

Shenzhen-based QuantumPharm Inc., trading as Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with...

Company Drug

GSK’s Blenrep and Star Pharma’s Topiramate Solution Target Priority Review in China

Fineline Cube Dec 18, 2024

The China’s Center for Drug Evaluation (CDE) website has signaled that GlaxoSmithKline’s (GSK; NYSE: GSK)...

Company Drug

Sciwind Biosciences’ Ecnoglutide Accepted for Review by NMPA for Weight Management

Fineline Cube Dec 18, 2024

Sciwind Biosciences Co., Ltd has received a significant boost as the National Medical Products Administration...

Company Deals

Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma

Fineline Cube Dec 18, 2024

In a significant development in the alternative asset management sector, companies such as Blackstone and...

Company Drug

Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA

Fineline Cube Dec 17, 2024

China-based Everest Medicines (HKG: 1952) has announced that the National Medical Products Administration (NMPA) has...

Drug

AstraZeneca’s ALXN2350 Selected for CDE’s Rare Disease Drug Development Program

Fineline Cube Dec 17, 2024

The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s...

Policy / Regulatory

NMPA’s CDE Releases Draft Proposal for Benefit-Risk Assessment in Global Drug Development

Fineline Cube Dec 17, 2024

The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has issued the...

Hospital

Perennial Real Estate Holdings’ Tianjin Hospital Earns Medical Practice License

Fineline Cube Dec 17, 2024

Singapore-based Perennial Real Estate Holdings Limited has announced that its Perennial General Hospital in Tianjin...

Company Drug

MSD Halts Development of Vibostolimab and Favezelimab Due to Trial Setbacks

Fineline Cube Dec 17, 2024

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed its decision to...

Company Deals

Adcendo ApS Expands Partnership with Biocytogen to Enhance ADC Pipeline

Fineline Cube Dec 17, 2024

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced that Denmark-based Adcendo ApS has...

Company Medical Device

MicroPort CardioFlow’s VitaFlow Liberty Receives Marketing Approval in Turkey

Fineline Cube Dec 17, 2024

China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has announced that its second-generation transcatheter aortic...

Posts pagination

1 … 184 185 186 … 606

Recent updates

  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.